Baclofen Deal Offers Amneal Biosimilars Advantage
Firm Accelerates Biosimilars Schedule, With Three Launches Now Planned For This Year
Amneal says an $83.5m deal to acquire Saol Therapeutics’ baclofen franchise will also bring the firm an “experienced institutional commercial team” that will be able to support three biosimilar launches that the company now expects to execute in 2022.
You may also be interested in...
Amneal highlighted the benefits of a broad spread of generics and an increased shift towards complex products with high barriers to entry, as it reported generics sales growth in Q1 despite a tough operating environment for US generics.
Amneal has received approval for its second US biosimilar in the form of the mAbxience-developed Alymsys rival to Avastin. The product represents just the third biosimilar version of bevacizumab to be approved in the US.
Amneal has announced the approval and launch of dexamethasone, azacitidine, carboprost and atropine in the US, as the company focuses on expanding its injectables portfolio with multiple launches to 2025.